{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.8","upperLimit":"34.6","value":"26.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"}],"units":"Participants"}],"description":"Objective disease response was defined as patients with a Complete Response, Unconfirmed Complete Response or a Partial Response (PR) according to the IWC 1999 assessed by an independent review committee: CR, Cru defined above, PR defined as ≥50% decrease in size of 6 largest dominant nodes and/or nodal masses \\& extranodal index lesions and no increase of non-index lesions, liver, or spleen; no new sites of disease evident; skin lesions decreased by ≥50%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG000","title":"Romidepsin"}],"paramType":"NUMBER","populationDescription":"Histologically Confirmed Population. Patients who discontinued prior to any response evaluation or who had no post-baseline assessment of response were classified as non-responders.","reportingStatus":"POSTED","timeFrame":"Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.","title":"Percentage of Participants With Objective Disease Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}